Questionnaire

This questionnaire saves your responses automatically every 20 seconds if you are interrupted while answering.

1. Compared with placebo, patients with symptomatic angina, ischaemia and CAD who received a coronary sinus reducer in the ORBITA-COSMIC study demonstrated:

2. Lerodalcibep is a:

3. The PROACT trial among anthracycline-treated patients with breast cancer or lymphoma found that the proportion of patients who experienced a troponin T release was:

4. Patients with moderate or severe HTG randomised to subcutaneous olezarsen every four weeks demonstrated:

5. In addition to standard care and compared with placebo, patients with an increased HF risk following acute MI and receiving empagliflozin in the EMPACT-MI trial demonstrated:

6. In the LIBerate-HR trial, >90% of participants in the lerodalcibep group achieved:

7.  The REDUCE-AMI trial of patients with MI who underwent early coronary angiography and had pLVEF found that beta-blocker therapy did not reduce the cumulative incidence of death from any cause, cardiovascular death, MI, hospitalisation for atrial fibrillation and hospitalisation for HF.

8. The AEGIS-II trial  demonstrated that compared to placebo in patients with multivessel CAD following MI, the composite outcome of cardiovascular death, MI and stroke in patients receiving infusions of human plasma-derived apoA-1 at four-weekly intervals was:

9. Findings of the ULTIMATE-DAPT trial of patients who had received DAPT for one month following PCI for an acute coronary syndrome include:

10. Zilebesiran targets hepatic synthesis of angiotensinogen, the upstream precursor of all angiotensin peptides.